Lyell Immunopharma Inc (NASDAQ:LYEL)’s traded shares stood at 1.14 million during the last session, with the company’s beta value hitting -0.40. At the close of trading, the stock’s price was $0.70, to imply an increase of 6.51% or $0.04 in intraday trading. The LYEL share’s 52-week high remains $3.26, putting it -365.71% down since that peak but still an impressive 27.14% since price per share fell to its 52-week low of $0.51.
Analysts have given a consensus recommendation of Hold for Lyell Immunopharma Inc (LYEL), translating to a mean rating of 3.50. Of 3 analyst(s) looking at the stock, 0 analyst(s) give LYEL a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 0 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.13.
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
After registering a 6.51% upside in the last session, Lyell Immunopharma Inc (LYEL) has traded red over the past five days. The 5-day price performance for the stock is 13.19%, and 11.78% over 30 days. With these gigs, the year-to-date price performance is 9.44%.
The extremes give us $1 and $1 for target low and target high price respectively. As such, LYEL has been trading -42.86% off suggested target high and -42.86% from its likely low.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
The rating firms project that company’s revenue will shrink -59.23% compared to the previous financial year.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -15.28% for the past 5-year period. While 2025 is set for a 23.30% return in earnings, projections for the next 5 years are at 17.62% annually.
LYEL Dividends
Lyell Immunopharma Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders
The next major institution holding the largest number of shares is ORLAND PROPERTIES LTD with 15.09 million shares, or about 5.91% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $21.89 million.
We also have Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund as the top two Mutual Funds with the largest holdings of the Lyell Immunopharma Inc (LYEL) shares. Going by data provided on Sep 30, 2024, Vanguard Total Stock Market Index Fund holds roughly 5.82 shares. This is just over 1.99% of the total shares, with a market valuation of $4.07 million. Data from the same date shows that the other fund manager holds a little less at 5.4, or 1.85% of the shares, all valued at about 3.78 million.
